BLGO BioLargo

BioLargo Engineering Awarded Additional U.S. Air Force Subcontract

BioLargo Engineering Awarded Additional U.S. Air Force Subcontract

Westminster, CA, July 31, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- BioLargo, Inc. (OTCQB:BLGO), developer of sustainable products and a full-service environmental engineering company, today announced that its engineering subsidiary has been awarded a third subcontract to provide air quality environmental engineering services to the United States Air Force. This new contract, for bases in Kansas and Illinois, follows the recent award of subcontracts to provide services to USAF bases in Texas and Arizona.   

The subcontracts are a result of “teaming agreements” with Bhate Environmental Associates, Inc. (), as prime-contractor, to prepare bids for submission to the U.S. General Services Administration (GSA) for environmental services on Air Force bases throughout the country. Bhate assembled a multi-disciplinary team of four companies, including BLEST, to provide services to the USAF in what is commonly referred to as “fence-to-fence environmental services” call orders.  These fence-to-fence (F2F) projects include a menu of environmental engineering services, which focus on hazardous waste, hazardous materials, air quality, water quality, natural and cultural resources. 

The total value of this contract awarded to Bhate is approximately $3 million over a five-year term, of which the subcontractors will receive a portion (first year guaranteed, and GSA can extend for four additional years). In addition to this awarded contract, BLEST is working closely with Bhate to pursue similar environmental projects for the USAF which are in various stages of bids and consideration.

Randall Moore, President of BioLargo Engineering, commented, “We are thankful to be working hand-in-hand with Bhate to serve our country and the US Air Force. We are hard at work on other similar bids for F2F project work.”

Dennis P. Calvert, President of BioLargo, Inc. commented, “We are thankful for the opportunity to serve and we are excited about the expanding list of opportunities ahead for the BioLargo family of companies.” 

About BioLargo, Inc.

BioLargo, Inc. is an innovative technology developer and environmental engineering company driven by a mission to "make life better" by delivering robust, sustainable solutions for a broad range of industries and applications, with a focus on clean water, clean air, and advanced wound care. We develop and commercialize disruptive technologies by providing the capital, support, and expertise to expedite them from "cradle" to "maturity" (). Our engineering division features experienced professional engineers dedicated to integrity, reliability, and environmental stewardship (). Our industrial odor control division, Odor-No-More () features CupriDyne Clean Industrial Odor Eliminator (), which eliminates the odor-causing compounds and VOCs rather than masking them, and is now winning over leading companies in the solid waste handling and wastewater industries and other industries that contend with malodors and VOCs. Our subsidiary BioLargo Water () develops the Advanced Oxidation System "AOS," a disruptive industrial water treatment technology designed to eliminate waterborne pathogens and recalcitrant contaminants with better energy-efficiency and lower operational costs than incumbent technologies. Our subsidiary Clyra Medical () features effective and gentle solutions for chronic wounds to promote infection control and regenerative tissue therapy.

Contact Information

Dennis Calvert President and CEO BioLargo, Inc. 888-400-2863

Safe Harbor Act

This press release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Actual results may differ from expectations, estimates and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results.

EN
31/07/2019

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BioLargo

Sean Conroy
  • Sean Conroy

BioLargo - Firing on all cylinders

BioLargo reported $666,000 in total Q320 sales (+24.7% y-o-y), a new record, a $1.9m operating loss (flat year-on-year) and a $2.39m net loss (from $3.89m in Q319). It had $356,000 in Q320 sales from ONM Environmental, down 10% from Q319, but the division recovered significantly since the start of the pandemic (up 19% from Q120). Sequentially, companywide revenue growth was up 56% over Q220, a strong bounce back from COVID-19 disruptions, and total sales are up 15% for 9M20 to $1.52m. BioLargo a...

Sean Conroy
  • Sean Conroy

BioLargo - Clyraguard to be a major growth driver

BioLargo stated that it expects Clyra Medical (of which it owns a 48% interest) and its Clyraguard product to be a major driver of growth in the coming periods. Clyra Medical signed an agreement with a major national distributor in July, with the first substantial sales to occur in Q320. Clyra Medical reported a small revenue ($21,000) for Q220, reflecting one week of sales from a previous test marketing run.

 PRESS RELEASE

Dennis P. Calvert, President & CEO of BioLargo, Inc. Provides Key Upda...

Dennis P. Calvert, President & CEO of BioLargo, Inc. Provides Key Updates and Outlook in a New Audio Interview with SmallCapVoice.com AUSTIN, Texas, June 08, 2020 (GLOBE NEWSWIRE) -- SmallCapVoice.com, Inc. (SCV) and BioLargo, Inc. (OTCQB:BLGO)(“the Company”), developer of sustainable technologies and a full-service environmental engineering company, today announced that a new audio interview with the Company is now available. The interview featuring an overview of BLGO’s current news and moves can be heard at . Dennis P. Calvert, President & CEO of BioLargo, discussed the Company’s bu...

Sean Conroy
  • Sean Conroy

BioLargo - Clyra launches Clyraguard

Clyra Medical, BioLargo’s partially owned (36%) subsidiary, recently announced that it registered with the FDA and launched Clyraguard, a disinfectant marketed for the treatment of non-critical surfaces such as personal protective equipment (PPE) that is non-irritating to skin. Concurrent with this BioLargo announced the results of two studies that showed Clyraguard and the company’s environmental product CupriDyne could both fully inactivate COVID-19.

Sean Conroy
  • Sean Conroy

BioLargo - A record-setting year

BioLargo reported record revenue of $1.86m for 2019, a 36% increase over 2018 and a record single quarter revenue of over $560,000 for Q4. Odor-no-More (ONM) had its best year to date with $1.46m in revenue ($832,000 gross profit). However, ONM fell short of its goal of breaking even for the year with a loss of $337,000 (albeit improved from the 2018 $433,000 loss) due to increased headcount for future growth. The company noted that in 2020 it will focus on increasing sales through improved dist...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch